Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders
Authors' conclusion
This study evaluated the clinical performance of the MedFrontier iFGF23 assay in a large cohort of XLH and TIO Caucasian and Asian patients. The clinical sensitivity of this iFGF23 assay is appropriate for clinical use.
Study context
- Population
- Patients with FGF23-dependent or FGF23-independent hypophosphatemia, normophosphatemic patients, chronic kidney disease (CKD) stage 2–5 patients and healthy controls
- Comparison
- Intact FGF23 across hypophosphatemic disorders, CKD and healthy controls
- TIOn = 42
- XLHn = 19
- FGF23-independent hypophosphatemian = 8
- Normophosphatemicn = 10
- CKD stage-2/3n = 15
- CKD stage-4/5n = 20
- Outcome
- Elevated iFGF23 vs healthy controls
Performance
As reported in the abstract
TIO vs Healthy controls: P = 0.0001 · XLH vs Healthy controls: P = 0.0001
Further findings
Correlation of iFGF23 with phosphate
- No significant correlation in TIO
- P = 0.74
- No significant correlation in XLH
- P = 0.86
iFGF23 vs eGFR in CKD
- Significant increase in serum iFGF23 as eGFR decreased
- ρ = −0.79, P ≤ 0.0001
Original publication
Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders. Endocr Pract. Published 7 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →